Tüdőrák: vizsgálatok itt: Franciaország
318 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Where
- Brest Cedex 2, Grenoble Cedex 9, Marseille, Saint-Herblain Cedex
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06667076 · EU 2025-520730-28-00 - 2. fázisTaking peopleA Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Where
- Brest, Marseille, Paris, Rouen Cedex, Villejuif
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT06667908 · EU 2024-518276-32-00 - 2. fázisTaking peopleStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Where
- Bron, Lyon Cedex 04, Marseille, Paris, Pierre-Bénite
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00 - No phaseTaking peopleERICA-02 Study : Impact of Physical Exercise on the Tumor Immune Microenvironment in Patients Treated With Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer
- Where
- Lyon, Villefranche-sur-Saône
- Életkor
- 18 év and over
- People
- 40
- Run by
- Centre Leon Berard
See details and how to joinNCT07786909 - 2/3. fázisTaking peopleSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Where
- Angers, Bayonne, Bordeaux, Bordeaux Cedex, Bron, Caen, Caen Cedex 5, Clermont-Ferrand, Créteil, Dijon, Grenoble Cedex 9, Limoges Cedex 1, Marseille, Mulhouse, Paris, Rennes Cedex 9, Saint-Herblain, Saint-Herblain Cedex, Strasbourg, Suresnes, Toulon, Toulon Cedex 9, Villejuif
- Életkor
- 18 év and over
- People
- 1580 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00 - 3. fázisNot yet taking people in FranciaországClinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Where
- Bordeaux, Bordeaux Cedex, Marseille Cedex 20, Montpellier, Nancy, Nantes Cedex 2, Nice Cedex 2, Paris, Pierre-Bénite, Rennes, Saint-Herblain, Saint-Herblain Cedex, Strasbourg, Villefranche Sur Saone Cedex
- Életkor
- 18 év to 90 év
- People
- 507 worldwide
- Run by
- ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00 - 3. fázisTaking peopleStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Where
- Bron, Caen, Lyon, Marseille, Saint-Herblain, Toulouse
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- ArriVent BioPharma, Inc.
See details and how to joinNCT07185997 - 3. fázisTaking peopleBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Bron, Marseille, Paris, Rennes Cedex 9, Saint-Herblain, Strasbourg, Toulouse, Villejuif
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00 - 2. fázisTaking peopleA Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
- Where
- La Roche Sur Yon Cedex 9, Marseille, Paris, Saint-Herblain, Saint-Herblain Cedex
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- Puma Biotechnology, Inc.
See details and how to joinNCT07465757 · EU 2026-525382-47-00 - 2/3. fázisTaking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Angers, Boulogne-Billancourt, Brest, Caen Cedex 5, Creteil Cedex, Grenoble Cedex 9, Limoges, Lorient, Marseille, Montpellier, Mulhouse, Paris, Saint-Herblain, Saint-Herblain Cedex, Strasbourg Cedex, Tours, Villejuif
- Életkor
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - 1. fázisTaking peoplePhase 1 Study of MK-1084 in KRAS mutant advanced solid tumors
- Életkor
- 18 év and over
- People
- 214 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05067283 · EU 2022-501563-40-00 - 1/2. fázisTaking peopleFirst-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- Where
- Bordeaux, Lille, Lyon, Marseille, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
- Életkor
- 18 év and over
- People
- 345 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT06043817 · EU 2023-506759-51-00 - 3. fázisTaking peopleA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Avignon, Bron, Créteil, Lille, Lyon, Marseille, Montpellier, Paris, Paris Cedex 20, Pessac, Villejuif
- Életkor
- 18 év and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- Avignon, La Rochelle, Lyon, Nimes Cedex 9, Rennes Cedex 9, Strasbourg Cedex, Suresnes, Toulon Cedex 9
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00 - 2. fázisNot yet taking people in FranciaországDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Angers, Dijon, Lyon, Marseille, Paris, Poitiers, Saint-Herblain Cedex
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - 1. fázisTaking peopleA Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- Where
- Bordeaux, Lyon, Pierre-Bénite, Villejuif
- Életkor
- 18 év and over
- People
- 404 worldwide
- Run by
- Astellas Pharma Inc
See details and how to joinNCT07094204 · EU 2025-522082-29-00 - No phaseNot yet taking people in FranciaországImpact of a Radiologic and Immunologic Signature on Cerebral Efficacy of Treatments in Lung Cancers With Brain Metastasis
- Where
- Bordeaux
- Életkor
- 18 év and over
- People
- 38
- Run by
- University Hospital, Bordeaux
See details and how to joinNCT07904013 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Where
- Avignon, La Rochelle, Lyon, Nimes Cedex 9, Rennes Cedex 9, Strasbourg Cedex, Suresnes, Toulon Cedex 9
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00 - 1/2. fázisTaking peopleA Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- Where
- Bordeaux, Dijon, Lille, Marseille, Toulouse, Villejuif
- Életkor
- 18 év and over
- People
- 235 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00 - 3. fázisTaking peopleA Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
- Where
- Angers, Avignon
- Életkor
- 18 év and over
- People
- 390 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT06931717 · EU 2024-519901-36-00 - 1/2. fázisTaking peopleA Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Where
- Bordeaux, Dijon, Limoges, Marseille, Nice Cedex 2, Paris, Saint-Herblain
- Életkor
- 18 év and over
- People
- 152 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01 - 1/2. fázisTaking peopleStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Where
- Angers, Bordeaux, Dijon, Montpellier, Nice Cedex 2, Paris, Saint-Herblain, Villejuif
- Életkor
- 18 év and over
- People
- 252 worldwide
- Run by
- AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00 - No phaseTaking peoplePredicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis
- Where
- Besançon, Dijon, Lyon
- Életkor
- 18 év and over
- People
- 378
- Run by
- Centre Georges Francois Leclerc
See details and how to joinNCT07376512 - 3. fázisTaking peopleA phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
- Where
- Avignon Cedex 9, Bayonne, Besancon Cedex, Bobigny, Brest Cedex 2, Bron, Cholet, Créteil, Grenoble Cedex 9, La Roche Sur Yon Cedex 9, Le Mans Cedex 9, Limoges, Lyon Cedex 04, Marseille, Montpellier Cedex 5, Mulhouse, Nancy Cedex, Paris, Pessac, Pierre-Bénite, Poitiers, Rennes, Saint-Herblain, Saint-Herblain Cedex, Strasbourg Cedex, Toulon Cedex 9, Toulouse, Villejuif
- Életkor
- 18 év and over
- People
- 340 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to join2023-509340-10-00 - No phaseTaking peopleAnalysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
- Where
- Aix-en-Provence, Albi, Amiens, Avignon, Bordeaux, Brest, Créteil, Dijon, Gleizé, Limoges, Lyon, Metz, Nantes, Paris, Pau, Pringy, Quimper, Reims, Rennes, Suresnes, Toulon, Toulouse, Tours, Troyes, TSA 50032 Toulouse, Valenciennes, Vandœuvre-lès-Nancy, Vannes
- Életkor
- 18 év and over
- People
- 90
- Run by
- Pfizer
See details and how to joinNCT06487078